PepGen reports FY2023 net loss $78.6M; cash runway into 2026 after $80M offering

PepGen Inc.

Enrollment complete for PGN-EDO51 5 mg/kg cohort; preliminary data expected mid-2024.
CONNECT2-EDO51 Phase 2 trial for DMD initiated in UK; designed to support accelerated approval.
FREEDOM-DM1 Phase 1 trial enrolling; preliminary data from 5 mg/kg cohort expected H2 2024.
Cash $110.4M as of Dec 31, 2023; combined with $80M Feb 2024 offering extends runway into 2026.
Net loss $78.6M for FY2023 vs $69.1M in FY2022; R&D expenses $68.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 6, 2024, PepGen Inc. announced its financial results for the year ended December 31, 2023 and other business updates.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-027111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.